Beyond Vanilla VC: Tough Times Demand Clever Measures
This article was originally published in Start Up
Executive Summary
A panel at Windhover's recent START-UP Forum made plain that venture capital is not an area--for all its interest in investing in innovation--which takes easily to innovation in its own business model. Panelists discussed some unusual approaches to financing and dealmaking--such as PIPEs (private investments in public equity) and the unique difficulties they bring. Investors are forming syndicates and becoming increasingly cautious; attaching strings to money in ways not deemed necessary before. In difficult and uncertain times like these, it's clear that investors need patience and fortitude, perhaps more than creativity.
You may also be interested in...
Novartis and Idenix Pursue Interdependent Growth
Novartis has capped a recent dealmaking spree with its most innovative deal yet--a half-acquisition of, half-alliance with, Idenix Pharmaceuticals. The big Swiss company agreed to pay $255 million to acquire a 51% equity stake in the private biotech company.
Investing in Hard Times
VCs worried about depressed financial markets and demanding Big Pharma customers are being tough on almost all start-ups seeking funding-but no tougher than on their existing portfolio companies. For some, hard times are creating opportunities. The circumstances of companies that raised money in the past few years are impacting newer firms now. Even organizations that met their milestones have seen valuations plummet, and are struggling to get financing. The down market is making it more desirable and easier for VCs to invest in late-stage start-ups. In-licensing has been popular, but investors are increasingly seeking value-priced components to fill out existing firms or launch new ones. Investors haven't stopped doing early-stage deals, but they're looking for firms with advantages that can reduce risk or cost, or speed a company to market. Drugmakers that used to sign big-money deals are now demanding that start-ups prove their technologies' merits through short-term, inexpensive pilot programs. Some firms aren't so pressed by hard times. VCs are promising stellar founders lots of support and time to take big risks they bet will pay off handsomely.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.